Atea Pharmaceuticals Inc expected to post a loss of 45 cents a share - Earnings Preview

Atea Pharmaceuticals

25/02/2023 03:06

* Atea Pharmaceuticals Inc  AVIR.OQ   AVIR.O  is expected
to show
a fall in quarterly revenue when it reports  results on February
28. 
    * 
    * ​Refinitiv's mean analyst estimate for Atea
Pharmaceuticals Inc
is for a loss of 45 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Atea
Pharmaceuticals Inc is $6​, above​ its last closing price
of $3.67. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.41       -0.44      -0.10     Beat    77.4
 Jun. 30 2022  -0.53       -0.52      -0.38     Beat    27.4
 Mar. 31 2022  -0.56       -0.58      -0.51     Beat    12.4​
 Dec. 31 2021  -0.01       0.17       1.34      Beat    704
 ​​Sep.        -0.12       -0.05      -0.34     Missed  -547.6
 30 2021                                                
 Jun. 30 2021  -0.10       0.01       0.02      Beat    300​
 Mar. 31 2021  -0.10       -0.05      0.34      Beat    718.2
 Dec. 31 2020  0.93        0.16       0.96      Beat    487.8
 This summary was machine generated February 25 at 03:05 GMT. 
All figures in US dollars  unless otherwise stated